DiaMedica Therapeutics earnings release, August 10, 2026

DiaMedica Therapeutics Inc. (DMAC) · Form 8-K, Item 2.02 · Filed · SEC filing

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Minneapolis, Minnesota – August 10, 2026 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended

June 30, 2026. Management will host a conference call Tuesday, August 11, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 2026 financial results.

“With the recent positive interim results from Part 1a of our Phase 2 study evaluating DM199 in preeclampsia, we’re eager to continue advancement of this promising candidate to address ischemic diseases in the second half of this year,” said Rick Pauls, President and CEO of DiaMedica. “Preeclampsia, fetal growth restriction and stroke are areas with high unmet medical need due to the lack of approved treatment options, and we believe DM199 has the potential to provide a disease-modifying solution for patients suffering from these ischemic conditions. We look forward to sharing results of the recently completed first cohort of fetal growth restriction and initiating subsequent studies in the ongoing investigator-sponsored Phase 2, open label trial in these indications.”

“In Part 1a of the Phase 2 study evaluating DM199 in women with preeclampsia with expected delivery within 72 hours, the most clinically meaningful pharmacodynamic effects were observed in the mid-dose range, Cohorts 4 through 8, where patients showed reductions in both maternal blood pressure and uterine artery pulsatility index (PI). Reductions in PI are consistent with reduced uteroplacental vascular resistance, improved blood flow and the potential to modify the underlying disease process in these patient populations,”said Julie Krop, MD, Chief Medical Officer of DiaMedica. “These findings represent significant progress for our preeclampsia program as they support selection of the mid-dose range for further clinical evaluation in our early-onset preeclampsia and fetal growth restriction studies.”

Recent Corporate Highlights

Detailed Part 1a results, including pharmacokinetic and pharmacodynamic analyses, are expected to be presented at an upcoming medical conference and submitted for publication.

DiaMedica is also preparing to initiate a concurrent open-label three dose Phase 2 study in early-onset preeclampsia in North America and the United Kingdom to further support Phase 3 dose selection.

Financial Results Highlights for the Quarter Ended June 30, 2026

Conference Call and Webcast Information

DiaMedica Management will host a conference call and webcast to discuss its business update and second quarter 2026 financial results on Tuesday, August 11, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company’s website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 18, 2026, by dialing (880) 770-2030 (US Toll Free) and entering the replay passcode: 2224408#.

About the Phase 2 IST of DM199 in Preeclampsia and Fetal Growth Restriction

The Phase 2 study is an open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored trial of DM199 for the treatment of PE is currently being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies (Part 1a, Part 1b and Part 2) in PE and a single study in FGR. Part 1a has been completed; the FGR study has initiated enrollment, and its first cohort of 6 participants has been enrolled; and Parts 1b and 2 are expected to initiate in September or October of 2026, as follows:"

Preeclampsia (PE)

Fetal Growth Restriction (FGR)

About Fetal Growth Restriction

Fetal growth restriction (FGR) occurs when a fetus fails to reach its genetically determined growth potential in the womb, most commonly due to placental insufficiency. FGR affects an estimated 10% of pregnancies worldwide and is associated with significantly increased risks of stillbirth, preterm birth, and neonatal morbidity, as well as long-term neurodevelopmental, cardiovascular, and metabolic complications. In severe, early-onset cases, FGR often necessitates delivery before 32 weeks of gestation, when the risks of prematurity must be weighed against the dangers of continued growth restriction in utero. See the recently released white paper, “

The Potential of DM199 to Treat Fetal Growth Restriction”.

About Preeclampsia... (truncated)re supposed to dilate to promote healthy blood flow to the placenta do not widen. Stage 2 then occurs after 20 weeks of pregnancy as the placenta, which has been chronically starved of oxygen from the blood, begins to release noxious factors into the mother’s circulation, inflicting widespread damage to her blood vessels and causing systemic endothelial dysfunction. Symptoms may include severe headaches, vision changes, upper abdominal pain and swelling in the hands and face. Delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia. Women who have had preeclampsia have three to four times the risk of high blood pressure and double the risk for heart disease and stroke.

About Acute Ischemic Stroke

Acute ischemic stroke (AIS) occurs when a blood clot blocks a vessel supplying blood to the brain, leading to a sudden loss of oxygen and nutrients and, if not corrected, ultimately neuronal cell death. According to the U.S. Center for Disease Control, stroke causes approximately one out of every 20 deaths in the U.S. each year, and nearly nine out of 10 strokes are ischemic. No new therapeutics have been approved for acute ischemic stroke in over 25 years. When a blood vessel in the brain becomes blocked during a stroke, a core area of the affected brain tissue will typically suffer a nearly complete loss of blood flow, while the surrounding area (the “ischemic penumbra”) receives only about 20-40% of normal blood flow. Cells in the core area are rapidly depleted of their oxygen and glucose stores, leading, often within minutes, to cell death. The cells in the penumbral area may remain viable for several hours but are eventually at risk of damage.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating expenses:Research and development8,1535,82216,14011,478
Operating expenses:General and administrative2,3452,1854,8404,673
Operating expenses:Operating loss-10,498-8,007-20,980-16,151
Operating expenses:Other income, net366314813757
Operating expenses:Loss before income tax expense-10,132-7,693-20,167-15,394
Operating expenses:Income tax expense-7-6-14-12
Operating expenses:Net loss-10,139-7,699-20,181-15,406
Other comprehensive lossUnrealized loss on marketable securities-11-19-87-37
Other comprehensive lossNet loss and comprehensive loss-10,150-7,718-20,268-15,443
Other comprehensive lossBasic and diluted net loss per share-0.19-0.18-0.38-0.36
Other comprehensive lossWeighted average shares outstanding – basic and diluted53,894,29542,957,61953,844,17142,901,093

Balance Sheet

June 30, 2026 — (In thousands, except share amounts)

June 30, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents5,12915,647
Current assets:Marketable securities38,37544,243
Current assets:Prepaid expenses and other assets567481
Current assets:Amounts receivable244258
Current assets:Total current assets44,31560,629
Non-current assets:Operating lease right-of-use asset, net400400
Non-current assets:Property and equipment, net153197
Non-current assets:Deposits133145
Non-current assets:Total non-current assets686742
Non-current assets:Total assets45,00161,371
Current liabilities:Accounts payable2,8121,475
Current liabilities:Accrued liabilities3,6663,545
Current liabilities:Operating lease obligation107101
Current liabilities:Finance lease obligation911
Current liabilities:Total current liabilities6,5945,132
Non-current liabilities:Operating lease obligation69124
Non-current liabilities:Finance lease obligation4
Non-current liabilities:Total non-current liabilities69128
Shareholders’ equity:Paid-in capital231,324228,829
Shareholders’ equity:Accumulated other comprehensive income (loss)-3750
Shareholders’ equity:Accumulated deficit-192,949-172,768
Shareholders’ equity:Total shareholders’ equity38,33856,111
Shareholders’ equity:Total liabilities and shareholders’ equity45,00161,371

Cash Flow

Six Months Ended June 30, — (Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net loss-20,181-15,406
Adjustments to reconcile net loss to net cash used in operating activities:Share-based compensation1,9401,638
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of discounts on marketable securities-359-441
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash lease expense4440
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation2314
Changes in operating assets and liabilities:Amounts receivable1475
Changes in operating assets and liabilities:Prepaid expenses and other assets-86-453
Changes in operating assets and liabilities:Deposits1,108
Changes in operating assets and liabilities:Accounts payable1,337321
Changes in operating assets and liabilities:Accrued liabilities and operating lease liabilities72-1,643
Changes in operating assets and liabilities:Net cash used in operating activities-17,196-14,747
Cash flows from investing activities:Purchase of marketable securities-23,650-16,370
Cash flows from investing activities:Maturities and sales of marketable securities29,79031,967
Cash flows from investing activities:Purchases of property and equipment-11-18
Cash flows from investing activities:Net cash provided by investing activities6,12915,579
Cash flows from financing activities:Proceed from the exercise of common stock options555257
Cash flows from financing activities:Principal payments on finance lease obligation-6-5
Cash flows from financing activities:Net cash provided by financing activities549252
Cash flows from financing activities:Net increase (decrease) in cash and cash equivalents-10,5181,084
Cash flows from financing activities:Cash and cash equivalents at beginning of period15,6473,025
Cash flows from financing activities:Cash and cash equivalents at end of period5,1294,109
Supplemental disclosure of non-cash transactions:Cash paid for income taxes1312
Full release

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expectations. When used in this press release, the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” or “would,” the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the timing, nature and requirements for regulatory applications and approvals, including its application for an IND for the study of DM199 as a treatment for preeclampsia and fetal growth restriction and its conducting a Phase 2 trial in these indications; continued ReMEDy2 trial enrollment and timing of the interim analysis; anticipated clinical benefits and success of DM199 for the treatment of preeclampsia, fetal growth restriction and acute ischemic stroke; future R&D and G&A expenses and the Company’s projected cash runway. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the timing and outcomes of non-clinical studies; risks and uncertainties relating to the timing of studies and trials; risks and uncertainties relating to the clinical expansion into preeclampsia and associated trials; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; DiaMedica’s plans to develop, obtain regulatory approval for and commercialize its DM199 product candidate for the treatment of preeclampsia, fetal growth restriction, and acute ischemic stroke and its expectations regarding the benefits of DM199; DiaMedica’s ability to conduct successful clinical testing of DM199 and within its anticipated parameters, site activations, enrollment numbers, costs and timeframes; the perceived benefits of DM199 over existing treatment options; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain shortages on DiaMedica’s business and clinical trials, including its ability to meet its site activation and enrollment goals; DiaMedica’s reliance on collaboration with third parties to conduct clinical trials; DiaMedica’s ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia, fetal growth restriction, and acute ischemic stroke; and the risks identified under the heading “Risk Factors” in DiaMedica’s annual report on Form 10-K for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports, including our most recent quarterly report on Form 10-Q. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Contact:

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118 skellen@diamedica.com

For Investor Inquiries:

Mike Moyer

Managing Director, LifeSci Advisors, LLC

Phone: (617) 308-4306 mmoyer@lifesciadvisors.com

Media Contact:

Madelin Hawtin

LifeSci Communications mhawtin@lifescicomms.com

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

DiaMedica Therapeutics Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.